BNT163b2 safety in patients with PIMS-TS/MIS-C history
Published: 13 February 2023| Version 1 | DOI: 10.17632/2tx87f76b6.1
Contributors:
, , , , , , , , , , , Description
This dataset includes the data for a prospective cohort study evaluating of Pfizer-BioNTech COVID-19 mRNA bnt163b2 vaccine (Comirnaty®) safety and T-cell and B-cell reactogenicity among patients with the anamnesis of paediatric inflammatory syndrome temporally associated with COVID-19 (PIMS) and among healthy controls without such an anamnesis. There is a table with processed results, as well as a folder containing raw flow cytometry results. The ethical approval was obtained from the Bioethics Committee at Wroclaw Medical University (CWN UMW BW: 313/2020 and CWN UMW BW 42/2022).
Files
Categories
Medicine, Pediatrics, Vaccine, COVID-19